Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 6, 2020, to announce its financial results for the fourth quarter and full year of 2019. The report primarily serves to furnish the company's earnings press release and supplemental information, which are key documents for investors seeking to understand the company's performance and financial condition. Investors should refer to the furnished exhibits, specifically Exhibit 99.1 (Earnings Press Release) and Exhibit 99.2 (Supplemental Information), for detailed financial figures and operational commentary. While the 8-K itself does not contain the detailed financial results, it directs investors to the official press release and website for this critical information. The press release, dated February 6, 2020, would have contained the company's revenue, earnings per share (EPS), net income, and other key performance indicators for the periods ending December 31, 2019. Understanding these results is crucial for evaluating BMY's recent performance, especially following any significant corporate events or market dynamics during 2019.
Key Highlights
- 1BMY filed an 8-K on February 6, 2020, to report Q4 and full-year 2019 financial results.
- 2The report incorporates by reference the company's Earnings Press Release (Exhibit 99.1) dated February 6, 2020.
- 3Supplemental financial information is also furnished via Exhibit 99.2, available on the company's website.
- 4Investors must consult the furnished press release and supplemental information for detailed financial performance data.
- 5This filing serves as the official notification of BMY's 2019 year-end financial outcomes.
- 6The exhibits provide insights into revenue, profitability, and other key metrics for Q4 and FY 2019.